Bio Path Holdings Inc Quick Ratio (BPTH) starting from the first quarter 2026 to first quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
BPTH's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth
In the wake of the increase in Current Liabilities in the first quarter 2026, Quick Ratio fell to 0 a new company low.
Within Major Pharmaceutical Preparations industry 419 other companies have achieved higher Quick Ratio than Bio Path Holdings Inc in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 0 to 3925.
Bio-Path Holdings Secures Funding through Private Placement, Aims to Bolster Cancer Drug Development Houston-based biotechnology company, Bio-Path Holdings, Inc., has recently announced a definitive agreement for the issuance and sale of shares of its common stock, alongside series A and short-term series B warrants, in a private placement priced at-the-market under Nasdaq rules. The company aims to raise an aggregate of $4.0 million through this funding, which will be utilized to further advance its portfolio of targeted nucleic acid cancer drugs. The offering is expected to close on or about June 5, 2024, subject to customary closing conditions. Bio-Path Holdings is renowned for its proprietary DNAbilize liposomal delivery and antisense technology, which has shown significant potential in developing innovative cancer treatment solutions. By leveraging these unique resources, the company aims to address the unmet medical needs in oncology and provide novel therapies to patients.
On the trailing twelve months basis In Spite of the unchanged in Current Liabilities in the Q1 2026 to $9.15 millions, cumulative Quick Ratio
